O'Shaughnessy Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $607K | Buy |
4,829
+1,599
| +50% | +$201K | ﹤0.01% | 1281 |
|
|
2025
Q1 | $357K | Sell |
3,230
-543
| -14% | -$60.1K | ﹤0.01% | 1482 |
|
|
2024
Q4 | $515K | Sell |
3,773
-36
| -0.9% | -$4.91K | ﹤0.01% | 1272 |
|
|
2024
Q3 | $444K | Sell |
3,809
-461
| -11% | -$53.7K | ﹤0.01% | 1285 |
|
|
2024
Q2 | $588K | Buy |
4,270
+575
| +16% | +$79.2K | 0.01% | 1063 |
|
|
2024
Q1 | $510K | Buy |
3,695
+531
| +17% | +$73.2K | 0.01% | 1093 |
|
|
2023
Q4 | $417K | Buy |
3,164
+109
| +4% | +$14.4K | 0.01% | 1084 |
|
|
2023
Q3 | $344K | Buy |
+3,055
| New | +$344K | 0.01% | 1054 |
|
|
2023
Q2 | – | Sell |
-2,366
| Closed | -$239K | – | 1553 |
|
|
2023
Q1 | $239K | Sell |
2,366
-543
| -19% | -$55K | ﹤0.01% | 1142 |
|
|
2022
Q4 | $347K | Buy |
2,909
+365
| +14% | +$43.6K | 0.01% | 917 |
|
|
2022
Q3 | $270K | Buy |
+2,544
| New | +$270K | 0.01% | 976 |
|
|
2021
Q4 | – | Sell |
-1,224
| Closed | -$118K | – | 2019 |
|
|
2021
Q3 | $118K | Sell |
1,224
-1,077
| -47% | -$104K | ﹤0.01% | 1304 |
|
|
2021
Q2 | $224K | Buy |
2,301
+37
| +2% | +$3.6K | ﹤0.01% | 973 |
|
|
2021
Q1 | $220K | Sell |
2,264
-259
| -10% | -$25.2K | ﹤0.01% | 891 |
|
|
2020
Q4 | $242K | Buy |
2,523
+738
| +41% | +$70.8K | 0.01% | 765 |
|
|
2020
Q3 | $172K | Buy |
1,785
+570
| +47% | +$54.9K | 0.01% | 747 |
|
|
2020
Q2 | $148K | Buy |
+1,215
| New | +$148K | ﹤0.01% | 740 |
|
|
2020
Q1 | – | Sell |
-23
| Closed | -$2K | – | 1619 |
|
|
2019
Q4 | $2K | Buy |
+23
| New | +$2K | ﹤0.01% | 1664 |
|